论文部分内容阅读
目的探索乙型肝炎病毒(HBV)基因型与拉米夫定、α-2b干扰素序贯治疗及单独予拉米夫定、α-2b干扰素治疗HBeAg阳性慢性乙型肝炎患者的疗效的相关性。方法HBeAg阳性慢乙肝患者,来自北京等四城市。分别拉米夫定、干扰素序贯治疗48周、拉米夫定48周或干扰素24周。停药后随访24周。评价HBV基因型与抗病毒治疗应答的关系。PCR-RFLP方法检测HBV基因型、基因亚型。结果225例患者中C基因型184例,其中C2亚型165例;B基因型41例,均为Ba亚型。治疗结束、随访结束时,各治疗组B型与C型间病毒学应答、血清学应答及完全应答率差异均无显著性。结论该四城市HBeAg阳性慢乙肝患者HBV基因型以B型和C型为主,亚型以Ba和C2亚型为主。治疗结束、随访结束时,各治疗组B型与C型间疗效无差异。
Objective To explore the relationship between hepatitis B virus (HBV) genotypes and sequential therapy of lamivudine and interferon alfa-2b and the curative effect of lamivudine and interferon-alpha 2b on patients with HBeAg-positive chronic hepatitis B Sex. Methods HBeAg-positive patients with chronic hepatitis B from Beijing and other four cities. Lamivudine, interferon for 48 weeks, lamivudine for 48 weeks, or interferon for 24 weeks. Follow-up after 24 weeks of withdrawal. To evaluate the relationship between HBV genotypes and antiviral therapy response. PCR-RFLP method to detect HBV genotypes, genotypes. Results There were 184 C genotypes in 225 patients, of which 165 were C2 subtype and 41 were B genotype, all of which were Ba subtype. At the end of treatment and at the end of follow-up, there was no significant difference in virological response, serological response and complete response rate between type B and C in each treatment group. Conclusion HBV genotypes of HBeAg-positive chronic hepatitis B patients in the four cities are mainly B and C genotypes, and subtype genotypes are mainly Ba and C2 subtypes. Treatment ended, at the end of follow-up, the treatment group B and C type no difference between the efficacy.